ACTG 144--DDI IN SYMPTOMATIC HIV CHILDREN WHO ARE UNRESPONSIVE/INTOLERANT TO ZDV

ACTG 144——对 ZDV 无反应/不耐受的有症状 HIV 儿童的 DDI

• 批准号: 3766545
• 负责人: MARILYN G DOYLE
• 金额: --
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766545
• 关键词: 2'3' dideoxyinosine; AIDS therapy; HIV infections; antiAIDS agent; child (0-11); clinical trials; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; microorganism disease chemotherapy; oral administration; pediatric AIDS; pediatric pharmacology

The purpose of this study is to compare the efficacy of two doses of oral ddI, determined by overall survival, changes in neurologic and neuropsychological functioning, and growth status. It will also evaluate the safety and tolerance of the two doses as determined by the following parameters: pancreatic, muscular, hepatic, and neurologic toxicity.

本研究的目的是比较两种剂量的口服 ddI，由总生存期、神经系统和 神经心理功能和生长状况。 它还将评估 两种剂量的安全性和耐受性由以下因素确定 参数：胰腺、肌肉、肝脏和神经毒性。